Actelion Announces Full Year 2007 Financial Results
21 févr. 2008 01h00 HE
|
Actelion Ltd.
-- Total net revenues of CHF 1.32 billion, up 39 percent
-- Tracleer(r) sales up 31 percent to CHF 1.18 billion
-- Cash EBIT of CHF 471.4 million, up 47 percent
-- U.S. GAAP operating profit of...
Actelion Reports Total Net Revenues for 2007
21 janv. 2008 01h00 HE
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Jan. 21, 2008 (PRIME NEWSWIRE) -- Actelion Ltd (VTX:ATLN) (Other OTC:ALIOF) today announced un-audited 2007 total net revenues of CHF 1'317.4 million (FY 2006: CHF...
Actelion Enters Phase III With Novel Orexin Receptor Antagonist Almorexant
20 déc. 2007 11h35 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 20, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the company has initiated the comprehensive Phase III program RESTORA (REstore physiological...
Phase III Study Initiated With Actelion-1 -- Highly Potent Tissue-targeting Endothelin Receptor Antagonist; Largest Study Ever in PAH to Demonstrate Morbidity/Mortality Benefits
19 déc. 2007 11h35 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLG) announced today the initiation of the phase III study SERAPHIN (Study with an Endothelin Receptor Antagonist in...
Actelion Provides Update On Bosentan in Metastatic Melanoma
17 déc. 2007 01h00 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 17, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that preliminary efficacy data generated in the proof-of-concept study evaluating bosentan (500mg bid)...
Actelion/Merck & Co., Inc. Renin Alliance Achieves Fourth Milestone -- Dosing in Phase II Initiated -- Actelion Receives USD10 Million
05 déc. 2007 11h50 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 5, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today that the renin alliance with Merck & Co., Inc. has achieved its fourth milestone. The alliance has...
Management Change At Actelion -- Otto Schwarz to Join as New Head of Business Operations
29 nov. 2007 11h35 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Nov. 29, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLG) announced today that Otto Schwarz will join the company as its new Head of Business Operations on 14 January 2008. He...
Actelion: Pivlaz (Clazosentan) Phase III Study Initiated to Demonstrate Prevention of Vasospasm-Related Morbidity and All-Cause Mortality After Aneurysmal Subarachnoid Hemorrhage
12 nov. 2007 01h17 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Nov. 12, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the initiation of the phase III program, CONSCIOUS-2, for the endothelin receptor antagonist Pivlaz(r)...
Actelion Ltd: Miglustat (Zavesca) Receives Negative Opinion From the European Committee For Medicinal Products For Human Use For Extension of Indication For Niemann Pick Type C
19 oct. 2007 01h07 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Oct. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the...
Actelion Ltd: EARLY: First PAH Functional Class II Population Study Emphasizes Need to Diagnose and Treat PAH Early
03 sept. 2007 01h00 HE
|
Actelion Ltd.
VIENNA, Austria, Sept. 3, 2007 (PRIME NEWSWIRE) -- At the 2007 European Society of Cardiology (ESC) congress in Vienna, Actelion Ltd (SWX:ATLN) has presented full results from a Phase IIIb trial(1)...